Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. NYXH
NYXH logo

NYXH Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Nyxoah SA (NYXH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.540
1 Day change
1.43%
52 Week Range
11.870
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Nyxoah SA (NYXH) is not a strong buy at this time for a beginner, long-term investor. The technical indicators suggest a bearish trend, and there are no strong positive trading signals or catalysts to justify immediate action. While the company has shown revenue growth, its financials remain weak with significant net losses. Analyst ratings are mixed, with lowered price targets. Given the investor's profile and the current data, holding off on this investment for now is prudent.

Technical Analysis

The technical indicators for NYXH are bearish. The MACD is negative and expanding downward, the RSI is neutral at 30.323, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its S1 support level of 3.767, with resistance levels at 4.917 and 5.272.

Positive Catalysts

  • Robert Taub's significant shareholding (9.99%) could indicate confidence in the company's future.

Neutral/Negative Catalysts

  • Net income remains significantly negative at -$23.58M, and gross margin dropped by 2.31% YoY. Analysts have lowered price targets, and there is no recent congress trading data or strong trading trends. Technical indicators are bearish, and the stock is expected to have limited short-term upside.

Financial Performance

In Q3 2025, revenue increased by 55.77% YoY to $1.97M, but net income remains negative at -$23.58M, albeit improving by 38.23% YoY. EPS improved to -0.63, up 26% YoY, but gross margin dropped to 60.5%, down 2.31% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst ratings are mixed. Stifel maintains a Buy rating but lowered the price target from $12 to $11. Baird has a Neutral rating and reduced the price target from EUR 7 to EUR 5, citing potential paths to improved performance in 2026.

Wall Street analysts forecast NYXH stock price to rise
5 Analyst Rating
Wall Street analysts forecast NYXH stock price to rise
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.490
sliders
Low
5.82
Averages
10.41
High
13
Current: 3.490
sliders
Low
5.82
Averages
10.41
High
13
Stifel
Jonathan Block
Buy
downgrade
$12 -> $11
AI Analysis
2026-01-29
Reason
Stifel
Jonathan Block
Price Target
$12 -> $11
AI Analysis
2026-01-29
downgrade
Buy
Reason
Stifel analyst Jonathan Block lowered the firm's price target on Nyxoah to $11 from $12 and keeps a Buy rating on the shares as part of the firm's Animal Health, Sleep, and Vision overview for 2026.
Baird
Neutral
downgrade
2025-12-16
Reason
Baird
Price Target
2025-12-16
downgrade
Neutral
Reason
Baird lowered the firm's price target on Nyxoah to EUR 5 from EUR 7 and keeps a Neutral rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees "several potential paths to improved" share performance for the group in 2026.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for NYXH
Unlock Now

People Also Watch